ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia

Daniel Gaudet,Daniel A. Gipe,Robert Pordy,Zahid Ahmad,Marina Cuchel,Prediman K. Shah,Kuang Yuh Chyu,William J. Sasiela,Kuo Chen Chan,Diane Brisson,Etienne Khoury,Poulabi Banerjee,Viktoria Gusarova,Jesper Gromada,Neil Stahl,George D. Yancopoulos,G. Kees Hovingh

NEW ENGLAND JOURNAL OF MEDICINE（2017）

引用 250|浏览21

暂无评分

摘要

Evinacumab, a monoclonal antibody that blocks ANGPTL3, was administered to nine adults with homozygous familial hypercholesterolemia. At 4 weeks, LDL cholesterol was reduced by a mean of 49%, with a mean absolute change from baseline of −157 mg per deciliter.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要